Login / Signup

Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.

Anouk E MullerBrenda C M De WinterBirgit C P Koch
Published in: The Journal of antimicrobial chemotherapy (2024)
The suggested dosing regimens will result in exposures of cefepime and tazobactam that would be adequate for infections caused by ESBL-producing pathogens with a cefepime/tazobactam MICs up to 16 mg/L.
Keyphrases
  • gram negative
  • escherichia coli
  • multidrug resistant
  • klebsiella pneumoniae
  • air pollution
  • high intensity
  • clinical practice
  • peritoneal dialysis
  • end stage renal disease